查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
頭頸癌治療市場規模、份額和趨勢分析報告：按治療類型（化學療法、免疫療法、靶向療法）、給藥途徑、分銷渠道、地區、細分市場、2022-2030 年預測
市場調查報告書
商品編碼
1170875

頭頸癌治療市場規模、份額和趨勢分析報告：按治療類型（化學療法、免疫療法、靶向療法）、給藥途徑、分銷渠道、地區、細分市場、2022-2030 年預測

Head And Neck Cancer Therapeutics Market Size, Share & Trends Analysis Report By Therapy Type (Chemotherapy, Immunotherapy, Targeted Therapy), By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2022 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

頭頸癌藥物市場增長及趨勢

Grand View Research, Inc. 的一份新報告預測，到 2030 年，全球頭頸癌藥物市場將達到 35 億美元。從 2022 年到 2030 年，該市場預計將以 12.5% 的複合年增長率增長。頭頸癌 (HNC) 診斷和治療的不斷進步預計將推動市場增長，因為它比手術更具成本效益和針對性。各種類型的 HNC 患病率上升和老年人口增加是市場的主要驅動力。

根據癌症研究所的數據，到 2021 年，美國將有大約 54,000 人被診斷出患有不同類型的 HNC，並且將有大約 11,000 人死亡。大量飲酒、長時間暴露在陽光下、愛潑斯坦-巴爾病毒 (EBV) 等致癌病毒感染以及吸煙是全球各種頭頸癌發病的主要原因。被認為是病因。

據聯合國統計，到 2020 年，全球 60 歲以上的人口將達到約 7.27 億。此外，預計老年人口將從 2020 年的 9.3% 增加到 2050 年的 16%。衰老會削弱免疫系統，使人們更容易感染各種類型的 HNC，從而導致對治療該疾病的治療藥物的需求增加。

此外，為開發新型靶向藥物和多模式治療方法而增加的研發活動有望提高頭頸癌患者的生存率。例如，Merck/Debiopharm 的 Xevipanant 目前正處於治療鱗狀頭頸癌的 III 期臨床試驗階段。它還被美國FDA指定為突破性療法。

預計支持性報銷政策也將推動市場增長。一些組織為患者及其護理人員購買藥物提供經濟援助。例如，2022 年 7 月，Uk columbia cancer將卡培他濱、卡鉑、西妥昔單抗、順鉑、多西紫杉醇、多柔比星、氟尿嘧啶和亞葉酸鈣列入其有益藥物清單。此列表中包含的藥物有資格獲得批准適應症的報銷。

頭頸癌治療市場報告重點

按治療類型劃分，免疫治療細分市場在 2021 年佔據了最大的市場份額，這是由於支持性報銷政策的存在以及免疫治療藥物作為頭頸癌疾病的有效治療方法的高效性。

通過給藥途徑，口服給藥部分預計在預測期內增長最快。這是因為這種給藥途徑在罕見病患者中具有很高的安全性、有效性和耐受性

按分銷渠道劃分，零售和專業藥房部分在 2021 年主導了市場。這種優勢可能是由於腫瘤學家對專業藥房的偏好。腫瘤學家通常需要專業藥房，因此豐富的治療知識可以支持治療計劃並減輕行政負擔

預計亞太地區將成為預測期內增長最快的地區。該地區增長的背後是新產品進入該地區。例如，2020年，NMPA批准Merck & Co., Inc.開發的ERBITUX（西妥昔單抗）在中國用於治療頭頸癌患者。

目錄

第一章 調查方法和範圍

  • 市場細分
    • 段範圍
    • 區域範圍
  • 調查方法
  • 信息採購
    • 購買的數據庫
    • GVR 內部數據庫
    • 次要信息
    • 初步調查
    • 第一次調查的內容
  • 信息或數據分析
    • 數據分析模型
  • 市場製定和驗證
  • 型號詳情
    • 商品流向分析
      • 方法一：商品流動方法
      • 方法 2：使用自下而上的方法逐個國家/地區進行市場估算
      • 方法 3：使用自上而下的方法逐個國家/地區進行市場估算
  • 全球市場：複合年增長率計算
  • 調查假設
  • 主要 KoL 響應
  • 市場份額計算
  • 二級信息列表
  • 目的
  • 縮略語表

第二章執行摘要

  • 市場概況

第三章頭頸癌治療市場——行業展望

  • 市場系列展望
    • 父市場血統展望
    • 相關/子公司市場展望
  • 繪製滲透率和增長前景
  • 市場動態
    • 市場驅動力分析
      • 頭頸癌患病率增加
      • 老年人口不斷增長
      • 增加研發和強大的管道產品存在
      • 支持性報銷政策和日益增長的疾病意識
    • 市場約束因素分析
      • 缺乏安全性和有效性數據
      • 治療費用高
  • 頭頸癌治療市場分析工具
    • 行業分析 - 搬運工
    • SWOT 分析，按因素（政治和法律、經濟和技術）
      • 政治與法律
      • 經濟與社會
      • 技術
  • 贖回和監管場景
    • 北美
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 多邊環境協定
  • 重大交易和戰略聯盟
    • 新產品發布
    • 獲得
    • 擴張
    • 合夥
  • 管道分析

第 4 章頭頸癌治療市場分析：治療類型範圍，2018-2030 年（收入，百萬美元）

  • 頭頸癌治療市場：治療類型的變化分析
  • 化學處理
  • 免疫療法
  • 靶向治療

5 頭頸癌治療市場分析：劑量範圍路線，2018-2030（收入，百萬美元）

  • 頭頸癌治療市場：給藥途徑的變化分析
  • 注射
  • 口服

第 6 章頭頸癌治療市場分析：分銷渠道覆蓋範圍，2018-2030 年（收入，百萬美元）

  • 頭頸癌治療藥物市場：分銷渠道的變化分析
  • 零售和專業藥店
  • 醫院藥房
  • 網上藥店

第 7 章頭頸癌治療市場分析，區域範圍，2017-2030 年，（收入，百萬美元）

  • 2021 年和 2030 年區域市場份額分析
    • 北美
      • 美國
      • 加拿大
    • 歐洲
      • 英國
      • 德國
      • 法國
      • 意大利
      • 西班牙
    • 亞太地區
      • 日本
      • 中國
      • 印度
      • 澳大利亞
      • 韓國
    • 拉丁美洲
      • 巴西
      • 墨西哥
      • 阿根廷
    • 中東和非洲 (MEA)
      • 南非
      • 沙特阿拉伯
      • 南非

8 頭頸癌治療市場：競爭分析

  • 主要市場進入者的最新發展和影響分析
    • 安索夫矩陣
  • 公司分類
    • 創新者
      • 市場差異化因素
  • 供應商情況
    • 主要經銷商及渠道合作夥伴名單
    • 主要客戶
    • 2020 年主要參與者的市場份額分析
  • 上市公司
    • 公司市場分析
    • 競爭儀錶盤分析
  • 民營企業
    • 主要初創企業名單
  • Regional Network Map
  • 公司簡介
    • Eli Lilly and Company
      • 公司簡介
      • 財務績效
      • 產品基準
      • 戰略舉措
    • Sanofi
      • 公司簡介
      • 財務績效
      • 產品基準
      • 戰略舉措
    • Merck & Co., Inc.
      • 公司簡介
      • 財務績效
      • 產品基準
      • 戰略舉措
    • Clingen Group plc.
      • 公司簡介
      • 財務績效
      • 產品基準
      • 戰略舉措
    • Bristol-Mayers Squibb Company
      • 公司簡介
      • Affymetrix
      • 公司簡介
      • 財務績效
      • 產品基準
      • 戰略舉措
    • Takeda Pharmaceutical Company Limited
      • 公司簡介
      • 財務績效
      • 產品基準
      • 戰略舉措
    • Teva Pharmaceutical Industries Ltd
      • 公司簡介
      • 財務績效
      • 產品基準
      • 戰略舉措
    • F. Hoffmann-La Roche Ltd.
      • 公司簡介
      • 財務績效
      • 產品基準
      • 戰略舉措
Product Code: GVR-2-68038-125-2

Head And Neck Cancer Therapeutics Market Growth & Trends:

The global head and neck cancer therapeutics market size is expected to reach USD 3.5 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 12.5% from 2022 to 2030. Increasing advancements in the diagnosis and treatment of head and neck cancer (HNC) are anticipated to propel market growth, as they are cost-effective and more specific to target over surgeries. The increasing prevalence of different types of HNCs and the growing geriatric population are major drivers of the market.

According to the Cancer Research Institute, in 2021, approximately 54,000 people were diagnosed with different types of HNC and about 11,000 deaths were reported in the U.S. Heavy alcohol consumption, prolonged sun exposure, cancer-causing viral infection such as Epstein-Barr virus (EBV) and tobacco consumption are some of the major factors contribute to rising incidence of various head and neck cancers worldwide.

Furthermore, according to the United Nations, it was estimated that, in 2020, there were around 727 million people aged 60 years and above worldwide. In addition, the geriatric population is expected to increase from 9.3% in 2020 to 16% in 2050. Aging weakens the immune system and makes people susceptible to different types HNCs, consequently, increasing the demand for therapeutic drugs for the treatment of disease.

Moreover, an increase in R&D activities for the development of novel targeted drugs and a multidisciplinary therapeutic approach is expected to lead to an increased survival rate of patients suffering from head and neck cancers. For instance, Merck/Debiopharm's Xevinapant is currently in phase III clinical trials for the treatment of squamous head and neck cancer. It has received breakthrough therapy designation from the U.S. FDA.

Supportive reimbursement policies are also expected to drive market growth. Several organizations provide financial assistance to patients and their caregivers for purchasing medicines. For instance, in July 2022, British Colombia Cancer included Capecitabine, Carboplatin, Cetuximab, Cisplatin, Docetaxel, Doxorubicin, Fluorouracil, and Leucovorin Calcium in their benefit drug list. Drugs included in this list are applicable for reimbursement for approved indications.

Head And Neck Cancer Therapeutics Market Report Highlights:

  • By therapy type, the immunotherapy segment held the largest market share in 2021 due to the presence of supportive reimbursement policies and the higher efficacy of immunotherapy drugs as an effective treatment for head and neck cancer diseases
  • By route of administration, the oral segment is expected to be the fastest-growing segment during the forecast period. This can be attributed to the high safety, efficacy, and tolerability associated with this route of administration among rare disease patients
  • By distribution channel, the retail and specialty pharmacy segment dominated the market in 2021. This dominance can be attributed to the preference of oncologists for specialty pharmacies. Oncologists often need specialty pharmacies so that with extensive therapeutic knowledge, they can support treatment plans and relieve them from the administrative burden
  • Asia Pacific is expected to be the fastest-growing region during the forecast period. The growth of the region can be attributed to the entry of new products into the region. For instance, in 2020, NMPA approved ERBITUX (Cetuximab) developed by Merck and Co., Inc., to treat patients with head and neck cancer in China

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market Segmentation
    • 1.1.1 Segment scope
    • 1.1.2 Regional scope
    • 1.1.3 Estimates and Forecast Timeline
  • 1.2 Research Methodology
  • 1.3 Information Procurement
    • 1.3.1 Purchased Database
    • 1.3.2 GVR's Internal Database
    • 1.3.3 Secondary Sources
    • 1.3.4 Primary Research
    • 1.3.5 Details of Primary Research
  • 1.4 Information or Data Analysis
    • 1.4.1 Data Analysis Models
  • 1.5 Market Formulation & Validation
  • 1.6 Model Details
    • 1.6.1 Commodity Flow Analysis
      • 1.6.1.1 Approach 1: Commodity flow approach
      • 1.6.1.2 Approach 2: Country wise market estimation using bottom up approach
      • 1.6.1.3 Approach 3: Country wise market estimation using top down approach
  • 1.7 Global Market: CAGR Calculation
  • 1.8 Research Assumptions
  • 1.9 Key KoL Responses
  • 1.10 Market Share Calculations
  • 1.11 List of Secondary Sources
  • 1.12 Objectives
    • 1.12.1 Objective 1:
    • 1.12.2 Objective 2:
  • 1.13 List of Abbreviations

Chapter 2 Executive Summary

  • 2.1 Market Summary

Chapter 3 Head and Neck Cancer Therapeutics Market - Industry Outlook

  • 3.1 Market Lineage Outlook
    • 3.1.1 Parent Market Lineage Outlook
    • 3.1.2 Related/Ancillary Market Outlook
  • 3.2 Penetration & Growth Prospect Mapping
  • 3.3 Market Dynamics
    • 3.3.1 Market Drivers Analysis
      • 3.3.1.1 Increasing prevalence of head and neck cancers
      • 3.3.1.2 Rising geriatric population
      • 3.3.1.3 Increasing R&D and strong presence of pipeline product
      • 3.3.1.4 Supportive reimbursment policies and rising awareness about disease
    • 3.3.2 Market Restraint Analysis
      • 3.3.2.1 Paucity of data related to safety and efficacy
      • 3.3.2.2 High cost of treatments
  • 3.4 Head and Neck Cancer Therapeutics Market Analysis Tools
    • 3.4.2 Industry Analysis - Porter's
    • 3.4.3 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
      • 3.4.3.1 Political and Legal
      • 3.4.3.2 Economic & Social
      • 3.4.3.3 Technological
  • 3.5 Reimbursement & Regulatory Scenario
    • 3.5.1 North America
    • 3.5.1 Europe
    • 3.5.2 Asia Pacific
    • 3.5.3 Latin America
    • 3.5.4 MEA
  • 3.6 Major Deals & Strategic Alliances
    • 3.6.1 New Product Launch
    • 3.6.2 Acquisition
    • 3.6.3 Expansion
    • 3.6.4 Partnerships
  • 3.7 Pipeline analysis

Chapter 4 Head and Neck Cancer Therapeutics Market Analysis: Therapy Type Scope, 2018 - 2030 (Revenue, USD Million)

  • 4.1 Head and Neck Cancer Therapeutics Market: Therapy Type Movement Analysis
  • 4.2 Chemotherapy
    • 4.2.1 Chemotherapy market estimates and forecast, 2018 - 2030 (USD million)
  • 4.3 Immunotherapy
    • 4.3.1 Immunotherapy market estimates and forecast, 2018 - 2030 (USD million)
  • 4.4 Targeted Therapy
    • 4.4.1 Targeted therapy market estimates and forecast, 2018 - 2030 (USD million)

Chapter 5 Head and Neck Cancer Therapeutics Market Analysis: Route of Administration Scope, 2018 - 2030 (Revenue, USD Million)

  • 5.1 Head and Neck Cancer Therapeutics Market: Route of Administration Movement Analysis
  • 5.2 Injectables
    • 5.2.1 Injectables market estimates and forecast, 2018 - 2030 (USD million)
  • 5.3 Oral
    • 5.3.1 Oral market estimates and forecast, 2018 - 2030 (USD million)

Chapter 6 Head and Neck Cancer Therapeutics Market Analysis: Distribution Channel Scope, 2018 - 2030 (Revenue, USD Million)

  • 6.1 Head and Neck Cancer Therapeutics Market: Distribution Channel Movement Analysis
  • 6.2 Retail & Specialty Pharmacies
    • 6.2.1 Retail & specialty pharmacies market estimates and forecast, 2018 - 2030 (USD million)
  • 6.3 Hospital Pharmacies
    • 6.3.1 Hospital pharmacies market estimates and forecast, 2018 - 2030 (USD million)
  • 6.4 Online Pharmacies
    • 6.4.1 Online pharmacies market estimates and forecast, 2018 - 2030 (USD million)

Chapter 7 Head and Neck Cancer Therapeutics Market Analysis, Regional Scope, 2017-2030, (Revenue, USD Million)

  • 7.1 Market Share Analysis by Regional, 2021 & 2030
    • 7.1.1 North America
      • 7.1.1.1 North America market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.1.2 U.S.
      • 7.1.1.2.1 U.S. market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.1.3 Canada
      • 7.1.1.3.1 Canada market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.1.2 Europe
      • 7.1.2.1 Europe market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.2.2 U.K.
      • 7.1.2.2.1 U.K. market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.2.3 Germany
      • 7.1.2.3.1 Germany market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.2.4 France
      • 7.1.2.4.1 France market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.2.5 Italy
      • 7.1.2.5.1 Italy market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.2.6 Spain
      • 7.1.2.6.1 Spain market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.1.3 Asia Pacific
      • 7.1.3.1 Asia Pacific market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.3.2 Japan
      • 7.1.3.2.1 Japan market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.3.3 China
      • 7.1.3.3.1 China market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.3.4 India
      • 7.1.3.4.1 India market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.3.5 Australia
      • 7.1.3.5.1 Australia market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.3.6 South Korea
      • 7.1.3.6.1 South Korea market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.1.4 Latin America
      • 7.1.4.1 Latin America market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.4.2 Brazil
      • 7.1.4.2.1 Brazil market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.3.3 Mexico
      • 7.1.3.3.1 Mexico market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.3.4 Argentina
      • 7.1.3.4.1 Argentina market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.1.5 Middle East and Africa (MEA)
      • 7.1.8.1 Middle East & Africa market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.8.2 South Africa
      • 7.1.8.2.1 South Africa market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.3.3 Saudi Arabia
      • 7.1.3.3.1 Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.3.4 South Africa
      • 7.1.3.4.1 South Africa market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 8 Head and Neck Cancer Therapeutics Market: Competitive Analysis

  • 8.1 Recent Developments and Impact Analysis, by Key Market Participants
    • 8.1.1 Ansoff matrix`
  • 8.2 Company Categorization
    • 8.2.1 Innovators
      • 8.2.2.1 Market Differentiators
  • 8.3 Vendor Landscape
    • 8.3.1 List of Key Distributors And Channel Partners
    • 8.3.2 Key Customers
    • 8.3.3 Key Company Market Share Analysis, 2020
  • 8.4 Public Companies
    • 8.4.1 Comapany Market Position analysis
    • 8.4.2 Competitive dashboard analysis
  • 8.5 Private Companies
    • 8.5.1 List of Key Emerging Companies
  • 8.6 Regional Network Map
  • 8.8 Company Profiles
    • 8.8.1 Eli Lilly and Company
      • 8.8.1.1 Company overview
      • 8.8.1.2 Financial performance
      • 8.8.1.3 Product benchmarking
      • 8.8.1.4 Strategic initiatives
    • 8.8.2 Sanofi
      • 8.8.2.1 Company overview
      • 8.8.2.2 Financial performance
      • 8.8.2.3 Product benchmarking
      • 8.8.2.4 Strategic initiatives
    • 8.8.3 Merck & Co., Inc.
      • 8.8.3.1 Company overview
      • 8.8.3.2 Financial performance
      • 8.8.3.3 Product benchmarking
      • 8.8.3.4 Strategic initiatives
    • 8.8.4 Clingen Group plc.
      • 8.8.4.1 Company overview
      • 8.8.4.2 Financial performance
      • 8.8.4.3 Product benchmarking
      • 8.8.4.4 Strategic initiatives
    • 8.8.5 Bristol-Mayers Squibb Company
      • 8.8.5.1 Company overview
      • 8.8.5.2 Affymetrix
      • 8.8.5.3 Company overview
      • 8.8.5.4 Financial performance
      • 8.8.5.5 Product benchmarking
      • 8.8.5.6 Strategic initiatives
    • 8.8.6 Takeda Pharmaceutical Company Limited
      • 8.8.6.1 Company overview
      • 8.8.6.2 Financial performance
      • 8.8.6.3 Product benchmarking
      • 8.8.6.4 Strategic initiatives
    • 8.8.7 Teva Pharmaceutical Industries Ltd
      • 8.8.7.1 Company overview
      • 8.8.7.2 Financial performance
      • 8.8.7.3 Product benchmarking
      • 8.8.7.4 Strategic initiatives
    • 8.8.8 F. Hoffmann-La Roche Ltd.
      • 8.8.8.1 Company overview
      • 8.8.8.2 Financial performance
      • 8.8.8.3 Product benchmarking
      • 8.8.8.4 Strategic initiatives

List of Tables

  • TABLE 1 List of Secondary Sources
  • TABLE 2 List of Abbreviations
  • TABLE 3 Global Head and Neck Cancer Therapeutics Market, By Region, 2018 - 2030 (USD Million)
  • TABLE 4 Global Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • TABLE 5 Global Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 6 Global Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 7 North America Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • TABLE 8 North America Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 9 North America Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 10 U.S. Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • TABLE 11 U.S. Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 12 U.S. Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 13 Canada Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • TABLE 14 Canada Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 15 Canada Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 16 Europe Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • TABLE 17 Europe Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 18 Europe Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 19 Germany Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • TABLE 20 Germany Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 21 Germany Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 22 U.K. Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • TABLE 23 U.K. Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 24 U.K. Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 25 France Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • TABLE 26 France Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 27 France Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 28 Italy Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • TABLE 29 Italy Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 30 Italy Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 31 Spain Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • TABLE 32 Spain Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 33 Spain Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 34 Asia Pacific Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • TABLE 35 Asia Pacific Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 36 Asia Pacific Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 37 Japan Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • TABLE 38 Japan Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 39 Japan Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 40 China Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • TABLE 41 China Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 42 China Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 43 India Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • TABLE 44 India Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 45 India Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 46 South Korea Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • TABLE 47 South Korea Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 48 South Korea Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 49 Australia Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • TABLE 50 Australia Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 51 Austalia Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 52 Latin America Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • TABLE 53 Latin America Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 54 Latin America Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 55 Brazil Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • TABLE 56 Brazil Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 57 Brazil Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 58 Mexico Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • TABLE 59 Mexico Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 60 Mexico Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 61 Argentina Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • TABLE 62 Argentina Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 63 Argentina Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 64 Middle East & Africa Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • TABLE 65 Middle East & Africa Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 66 Middle East & Africa Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 67 Saudi Arabia Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • TABLE 68 Saudi Arabia Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 69 Saudi Arabia Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 70 South Africa Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • TABLE 71 South Africa Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 72 South Africa Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 73 UAE Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • TABLE 74 UAE Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 75 UAE Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

  • FIG. 1 Head and neck cancer therapeutics market segmentation
  • FIG. 2 Market research process
  • FIG. 3 Data triangulation techniques
  • FIG. 4 Primary research pattern
  • FIG. 5 Market research approaches
  • FIG. 6 Value-chain-based sizing & forecasting
  • FIG. 7 QFD modelling for market share assessment
  • FIG. 8 Market formulation & validation
  • FIG. 9 Head and neck cancer therapeutics market snapshot
  • FIG. 10 Parent market outlook
  • FIG. 11 Related/ancillary market outlook, revenue, 2021, (USD Million)
  • FIG. 12 Penetration and growth prospect mapping
  • FIG. 13 Head and neck cancer therapeutics market driver impact
  • FIG. 14 Head and neck cancer therapeutics market restraint impact
  • FIG. 15 SWOT analysis, by factor (political & legal, economic, and technological)
  • FIG. 16 Industry Analysis - Porter's
  • FIG. 17 Strategy mapping
  • FIG. 18 Head and neck cancer therapeutics market: Therapy type outlook and key takeaways
  • FIG. 19 Head and neck cancer therapeutics market: Therapy type movement analysis & market share 2021 & 2030
  • FIG. 20 Chemotherapy market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 21 Immunotherapy market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 22 Targeted therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 23 Head and neck cancer therapeutics market: Route of Administration outlook and key takeaways
  • FIG. 24 Head and neck cancer therapeutics market: Route of administration movement analysis & market share 2021 & 2030
  • FIG. 25 Injectable market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 26 Oral market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 27 Head and neck cancer therapeutics market: Distribution Channel outlook and key takeaways
  • FIG. 28 Head and neck cancer therapeutics market: Distribution Channel movement analysis & market share 2021 & 2030
  • FIG. 29 Retail & specialty pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 30 Hospital pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 31 Online pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 32 Head and neck cancer therapeutics: Regional outlook and key takeaways
  • FIG. 33 Regional outlook, 2021 & 2030
  • FIG. 34 North America
  • FIG. 35 North America market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 36 U.S.
  • FIG. 37 U.S. market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 38 Canada
  • FIG. 39 Canada market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 40 Europe
  • FIG. 41 Europe market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 42 U.K.
  • FIG. 43 U.K. market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 44 Germany
  • FIG. 45 Germany market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 46 France
  • FIG. 47 France market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 48 Italy
  • FIG. 49 Italy market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 50 Spain
  • FIG. 51 Spain market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 52 Asia Pacific
  • FIG. 53 Asia Pacific market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 54 Japan
  • FIG. 55 Japan market estimates and forecast, 2018 - 2030(USD Million)
  • FIG. 56 China
  • FIG. 57 China market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 58 India
  • FIG. 59 India market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 60 South Korea
  • FIG. 61 South Korea market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 62 Australia
  • FIG. 63 Australia market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 64 Latin America
  • FIG. 65 Latin America market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 66 Brazil
  • FIG. 67 Brazil market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 68 Mexico
  • FIG. 69 Mexico market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 70 Argentina
  • FIG. 71 Argentina market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 72 Middle East & Africa
  • FIG. 73 MEA market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 74 South Africa
  • FIG. 75 South Africa market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 76 Saudi Arabia
  • FIG. 77 Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 78 UAE
  • FIG. 79 UAE market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 80 Market differentiators
  • FIG. 81 Key company market share analysis, 2021
  • FIG. 82 Company market position analysis
  • FIG. 83 Competitive dashboard analysis
  • FIG. 84 Regional network map